TP 300
Alternative Names: CH0793076; TP300Latest Information Update: 16 Oct 2017
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharma Europe
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 22 Jul 2011 Suspended - Phase-II for Colorectal cancer in Europe (IV)
- 22 Jul 2011 Suspended - Phase-II for Gastric cancer in Europe (IV)
- 22 Jul 2011 Suspended - Phase-II for Gastric cancer in United Kingdom (IV)